Notch activation inhibits AML growth and survival: a potential therapeutic approach
Open accessThe DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index.
Abstract
Although aberrant Notch activation contributes to leukemogenesis in T cells, its role in acute myelogenous leukemia (AML) remains unclear. Here, we report that human AML samples have robust expression of Notch receptors; however, Notch receptor activation and expression of downstream Notch targets are remarkably low, suggesting that Notch is present but not constitutively activated in human AML. The functional role of these Notch receptors in AML is not known. Induced activation through any of the Notch receptors (Notch1–4), or through the Notch target Hairy/Enhancer of Split 1 (HES1), consistently leads to AML growth arrest and caspase-dependent apoptosis, which are associated with B cell lymphoma 2 (BCL2) loss and enhanced p53/p21 expression. These effects were dependent on the HES1 repressor domain and were rescued through reexpression of BCL2. Importantly, activated Notch1, Notch2, and HES1 all led to inhibited AML growth in vivo, and Notch inhibition via dnMAML enhanced proliferation in vivo, thus revealing the physiological inhibition of AML growth in vivo in response to Notch signaling. As a novel therapeutic approach, we used a Notch agonist peptide that led to significant apoptosis in AML patient samples. In conclusion, we report consistent Notch-mediated growth arrest and apoptosis in human AML, and propose the development of Notch agonists as a potential therapeutic approach in AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, Notch signaling functions as a tumor suppressor in the malignancies of myeloid origin, such as acute myelogenous leukemia and chronic myeloid leukemia [138, 139].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [138]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bioconductor: open software development for computational biology and bioinformatics
Gentleman, R. C., Carey, V. J., Bates, D. M., Bolstad, B., Dettling, M., Dudoit, S., Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004) · Genome Biology · doi:10.1186/gb-2004-5-10-r80 · Cited by 12,172
Notch Signaling: Cell Fate Control and Signal Integration in Development
Artavanis-Tsakonas, S., Rand, M. D., & Lake, R. J. (1999) · Science · doi:10.1126/science.284.5415.770 · Cited by 5,909
Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia
Weng, A. P., Ferrando, A. A., Lee, W., Morris, J. P., Silverman, L. B., Sanchez-Irizarry, C., Blacklow, S. C., Look, A. T., & Aster, J. C. (2004) · Science · doi:10.1126/science.1102160 · Cited by 2,715 · cited 2×
“…independent of which activated receptor was expressed, suggesting that a common downstream target expression had no effect on T-ALL cell line growth, whereas Notch inhibition via expression of dnMAML inhibited the growth of the MOLT4 and SUPT1 T-ALL lines, as expected (Weng et al., 2003, 2004).”
BackgroundResultProduction of high-titer helper-free retroviruses by transient transfection.
Pear, W. S., Nolan, G. P., Scott, M. L., & Baltimore, D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8392 · Cited by 2,266 · cited 1×
“The production of retroviral supernatant and transduction of each cell line was performed following previously established methods (Pear et al., 1993).”
MethodEllisen, L. W., Bird, J., West, D. C., Soreng, A. L., Reynolds, T. C., Smith, S. D., & Sklar, J. (1991) · Cell · doi:10.1016/0092-8674(91)90111-b · Cited by 1,696
Notch1 Expression in Early Lymphopoiesis Influences B versus T Lineage Determination
Pui, J. C., Allman, D., Xu, L., DeRocco, S., Karnell, F. G., Bakkour, S., Lee, J. Y., Kadesch, T., Hardy, R. R., Aster, J. C., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80105-3 · Cited by 949
Tibes, R., Qiu, Y., Lu, Y., Hennessy, B., Andreeff, M., Mills, G. B., & Kornblau, S. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0334 · Cited by 718 · cited 1×
“We probed a validated reversephase protein lysate array (RPPA) containing duplicate dilutions of total cell lysates from 560 AML patient samples, 10 normal CD34-selected controls, and 21 normal peripheral blood mononuclear cell controls (Tibes et al., 2006; Kornblau and Coombes, 2011).”
MethodSelf-citationPucci, B., Kasten, M., & Giordano, A. (2000) · Neoplasia · doi:10.1038/sj.neo.7900101 · Cited by 652
Saito, T., Chiba, S., Ichikawa, M., Kunisato, A., Asai, T., Shimizu, K., Yamaguchi, T., Yamamoto, G., Seo, S., Kumano, K., et al. (2003) · Immunity · doi:10.1016/s1074-7613(03)00111-0 · Cited by 561
Regulation of Breast Cancer Stem Cell Activity by Signaling through the Notch4 Receptor
Harrison, H., Farnie, G., Howell, S. J., Rock, R. E., Stylianou, S., Brennan, K. R., Bundred, N. J., & Clarke, R. B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-1681 · Cited by 543 · cited 1×
“Interestingly, AML and normal CD34+ cells expressed similar levels of Notch receptors 1–3, but AML samples expressed significantly higher Notch4, the Notch receptor classically associated with vascular endothelium (Wu et al., 2005) and breast cancer (Harrison et al., 2010).”
Cited by
Items 101–152 of 152
Hes1 upregulation contributes to the development of FIP1L1-PDGRA–positive leukemia in blast crisis
Uchida, T., Kitaura, J., Nakahara, F., Togami, K., Inoue, D., Maehara, A., Nishimura, K., Kawabata, K. C., Doki, N., Kakihana, K., et al. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.01.009 · Cited by 9
Vascular Notch Signaling in Stress Hematopoiesis
Huang, C., Yang, D., Ye, G. W., Powell, C. A., & Guo, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.606448 · Cited by 11
Luo, F., Zhang, C., Shi, Z., Mao, T., & Jin, L. H. (2024) · Insect Biochemistry and Molecular Biology · doi:10.1016/j.ibmb.2024.104176 · Cited by 8
Wang, Z., Yang, Q., Yang, Y., Liu, M., Zeng, J., Gan, L., Zhou, Q., Li, X., Yang, Z., Yang, Z., et al. (2025) · Stem Cell Reviews and Reports · doi:10.1007/s12015-025-11016-1 · Cited by 11
“In T cell ALL and chronic lymphocytic leukemia, Notch signal - ing is crucial for sustaining LSC survival and preventing differentiation [ 86–88].”
GSI promotes vincristine-induced apoptosis by enhancing multi-polar spindle formation
Singh, A., Zapata, M., Choi, Y. S., & Yoon, S.-O. (2013) · Cell Cycle · doi:10.4161/cc.26951 · Cited by 9
HES1 is an independent prognostic factor for acute myeloid leukemia
Tian, C., Tang, Y., Wang, T., Wang, Y., Zhang, Y., Wang, X., & Yu, Y. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s83511 · Cited by 8
“It is well known that HES1 is the target of Notch signaling which is reported to affect cell differentiation and maintain the cells in G0 phase in various tissues including the hematopoietic tissue.(7,8) Our previous studies reported that over-expression of HES1 inhibited cycling of hematopoietic stem and progenitor c…”
Bone's dark side: mutated osteoblasts implicated in leukemia
Schajnovitz, A., & Scadden, D. T. (2014) · Cell Research · doi:10.1038/cr.2014.26 · Cited by 7
Targeting gamma secretase: has progress moved up a Notch?
Dumbrava, E. E. I., Mills, G. B., & Yap, T. A. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy307 · Cited by 7
Hirano, M., Kimura, K., Ishigaki, T., Nojima, M., Daimon, M., Morita, H., Takenaka, K., Xu, B., Sawada, N., Hirokawa, M., et al. (2020) · Circulation Journal · doi:10.1253/circj.cj-20-0344 · Cited by 6
Identification of ANXA1 as a Novel Upstream Negative Regulator of Notch1 Function in AML
Shao, G. Q., Wang, X., Zheng, Y., Ma, J., Wang, L., Yan, Z., Sun, Z., Zhang, S., Wu, H., Lv, Y., et al. (2024) · Advanced Science · doi:10.1002/advs.202409726 · Cited by 5
Notch affects the prodifferentiating effect of retinoic acid and PMA on leukemic cells
Matulić, M., Skelin, J., Radić-Krišto, D., Kardum‐Skelin, I., Grčević, D., & Antica, M. (2014) · Cytometry Part A · doi:10.1002/cyto.a.22582 · Cited by 5
“While this paper was in revision, additional evidence for Notch involvement in acute myelogenous leukemia has been published (26,27).”
BackgroundVanlallawma, A., Lallawmzuali, D., Pautu, J. L., Scaria, V., Sivasubbu, S., & Kumar, N. S. (2022) · BMC Genomic Data · doi:10.1186/s12863-022-01037-x · Cited by 6
Shahrokh, B., Farsani, M. A., Gharehbaghian, A., Fatemeh, F., & Mohammadi, M. H. (2022) · Current Research in Translational Medicine · doi:10.1016/j.retram.2022.103375 · Cited by 5
Zhang, Z., Huang, R., & Lai, Y. (2023) · Scientific Reports · doi:10.1038/s41598-023-45626-x · Cited by 5
“Kannan et al. observed that activated Notch1 and Notch2 could inhibit the growth of AML cells in vivo and otherwise promote their growth of AML cells 45 .”
The Bone Marrow Niche – The Tumor Microenvironment That Ensures Leukemia Progression
Cardoso, B. A. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-34025-4_14 · Cited by 5
TP53 signal pathway confers potential therapy target in acute myeloid leukemia
Zhu, G., Cai, J., & Zhong, H. (2023) · European Journal Of Haematology · doi:10.1111/ejh.13934 · Cited by 5
“nists were proven to increase the expression of p53 protein accompanied by the decrease of BCL-2 and increase inhibition of AML cells.(44) Recently research in vivo illustrates that EGFL7 inhibits ligand binding silencing NOTCH in AML(45) and another in vitro study demonstrated that PRKD2 enhances the proliferation of…”
BackgroundInhibition of DOCK1 suppresses Notch signalling pathway and impairs leukaemogenesis
Lin, M., Hsu, Y.-C., Chiu, H., Yao, C., Liu, C., Kao, C., Yuan, C., Hsu, C., Yang, Y., Hou, H., et al. (2025) · British Journal of Haematology · doi:10.1111/bjh.20140 · Cited by 5
“21,22 In the current study, DOCK1 knockdown downregulated the expression of NOTCH2 and its down-stream target HES1 .”
Hes1 in malignant tumors: from molecular mechanism to therapeutic potential
Zhang, L., Zhang, Q., Guo, C., Ru, Z., Yang, Z., Geng, Y., Yang, J., Zhang, D.-G., Yang, Z., & Huang, S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1585624 · Cited by 11
Kontio, J., Pyhäjärvi, T., & Sillanpää, M. J. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1008960 · Cited by 4
“Furthermore, AMLspecific down-regulation of BAD/BCL2 plays a critical role in NOTCH-mediated apoptosis in AML [56].”
BackgroundBone marrow niches in myelodysplastic syndromes
Tosato, G., Feng, J., Ohnuki, H., & Sim, M. (2021) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2021.120 · Cited by 6
“Activation of Notch signaling initiated growth arrest and differentiation of AML cells, suggesting a tumor-suppressive function, which provides a rationale for using Notch agonists for the treatment of AML[98].”
BackgroundDistinct oncogenic phenotypes in hematopoietic specific deletions of Trp53
Palanichamy, J. K., Tran, T. M., King, J. K., Katzman, S. J., Ritter, A. J., Sharma, G., Tso, C., Contreras, J. R., Fernando, T. R., Sanford, J. R., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-33949-8 · Cited by 4
Nakamura, M., Wu, L., Griffin, J. D., Kojika, S., Goi, K., Inukai, T., & Sugita, K. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.07.022 · Cited by 4
Zhu, R., Shirley, C. M., Chu, S. H., Li, L., Nguyen, B., Seo, J., Wu, M. H., Seale, T. S., Duffield, A. S., Staudt, L. M., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02292-w · Cited by 3
Landscape and clinical impact of NOTCH mutations in newly diagnosed acute myeloid leukemia
Han, H., Yao, Y., Wang, H., Zhou, M., Zhang, Z., Xu, X., Qi, J., Liu, Y., Wu, D., & Han, Y. (2022) · Cancer · doi:10.1002/cncr.34534 · Cited by 3
“novel tumor suppressor, was validated to lead to growth arrest and apoptosis of AML‐initiating cells after activation.(38,39) Therefore, much work must be done to test the potential role of NOTCH in AML thoroughly.”
BackgroundMolecular determinants of etoposide resistance in HL60 cells
Alghamdi, R. H. (2022) · Bioinformation · doi:10.6026/97320630018894 · Cited by 3
A Novel Family of Lysosomotropic Tetracyclic Compounds for Treating Leukemia
Carbo, J. M. C. I., Cornet-Masana, J. M., Cuesta‐Casanovas, L., Delgado-Martínez, J., Banús‐Mulet, A., Clément-Demange, L., Serra, C., Catena, J., Llebaria, A., Esteve, J., et al. (2023) · Cancers · doi:10.3390/cancers15061912 · Cited by 3
“Here, EDK-87 and EDK-88 triggered a calcium-mediated signaling pathway that led to terminal differentiation through the modulation of TFEB activation and the subsequent downregulation of MYC, following the recently proposed role of lysosomes as key intracellular signaling hubs [44].”
BackgroundInfluentialActivating Notch ameliorates AML
Tse, M. T. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3982 · Cited by 3
Portillo, V., Chadwick, N., Lloyd, R., Jackson, D. A., & Buckle, A. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12200 · Cited by 3
“(31) have shown that Notch1 and Notch2 are both expressed on CD34 cells, but they found no evidence of receptor activation.”
BackgroundFlower isoforms mediate fitness selection of astrocytes through extracellular vesicles
Tu, S.-M., Lin, C.-H., Liu, Y., Schirra, C., Yang, C.-A., Hohneck, J., Jung, M., Clemenz, A., Rother, S., Aljohmani, A., et al. (2026) · EMBO Reports · doi:10.1101/2025.08.08.669265 · Cited by 1
Chen, B., & Li, C. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-809479-2.00010-x · Cited by 1
Li, C., Lai, T.-Y., & Chen, B. (2018) · Oncotarget · doi:10.18632/oncotarget.25318 · Cited by 1
“1) and p53 to induce cell proliferation during leukemogenesis [16, 17].”
Notch in Human Cancers—A Complex Tale
Guo, H., Xie, T., & Liu, H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00096-7 · Cited by 2
Huang, Y., Zhang, Y., Zhou, Q., Teng, Y., Sui, M., & Zhang, F. (2023) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2023.107093 · Cited by 1
The Special Role of JAK/STAT, and Notch Signaling Pathways in Cancer Pathogenesis
(2023) · Journal of Case Reports and Medical History · doi:10.54289/jcrmh2300135 · Cited by 1
RBPJ Role in Cancer Immunotherapy
Mohammadi, A., Faeed, M., Alijanzadeh, D., Zargar, M., Tabari, M. A. K., & Rezaei, N. (2024) · Springer eBooks · doi:10.1007/978-3-030-80962-1_403-1 · Cited by 1
NOTCH1 combined with chemotherapy synergistically inhibits triple-negative breast cancer
Chen, W.-J., Wu, H.-T., Lan, Y.-Z., Wu, Z. Q., Yu, X., Lin, W., & Liu, J. (2025) · World Journal of Clinical Oncology · doi:10.5306/wjco.v16.i6.106197 · Cited by 2
Notch Signaling in T-Cell Acute Lymphoblastic Leukemia and Other Hematologic Malignancies
Hoofd, C., Giambra, V., & Weng, A. P. (2018) · Springer eBooks · doi:10.1007/978-1-4939-8859-4_8 · Cited by 2
Notch Signaling: A Pivot Regulator of Adaptive and Innate Immunity
Kumai, T., & Rodríguez, P. C. (2018) · Springer eBooks · doi:10.1007/978-1-4939-8859-4_5 · Cited by 1
Aithal, M. G. S., & Narayanappa, R. (2015) · Encyclopedia of Life Sciences · doi:10.1002/9780470015902.a0024868
[Inhibitory effects of Hes1 on acute myeloid leukemia cells].
Tian, C., Jia, Y., Hu, D., Li, C., Qu, F., & Zhang, Y. (2015) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2015.06.008
“[7] Kannan S, Sutphin RM, Hall MG, et al.”
BackgroundTian, D., Liang, Y., & Zhang, Y. (2018) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2018.10.011
“[16] Kannan S, Sutphin RM, Hall MG, et al.”
BackgroundAmin, N. Y., Esheba, N. E. S., Khedr, G., El-enein, A. M. A., & Hamouda, S. A. (2022) · Journal of Advances in Medicine and Medical Research · doi:10.9734/jammr/2022/v34i2231598
Involvement of Notch signaling in interleukin-4-stimulated human macrophages
Sangphech, N. (2017) · Chula Digiverse · doi:10.58837/chula.the.2017.347
Stem Cells Signaling Modulators in Hematological Diseases
Ishtiaq, A., Hussain, K., Mushtaq, I., & Murtaza, I. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00052-4
Uchimura, R., Nishimura, S., Ozaki, M., Kurogi, M., Kawahara, K., Makise, M., & Kuniyasu, A. (2024) · ACS Omega · doi:10.1021/acsomega.4c08955
Role and Therapeutic Implication of Notch Signaling Pathway in Cancer
Lone, S. S., Khan, M. S., Majid, S., & Qureshi, W. (2025) · Springer eBooks · doi:10.1007/978-981-96-2763-9_6
RBPJ Role in Cancer Immunotherapy
Mohammadi, A., Faeed, M., Alijanzadeh, D., Zargar, M., Tabari, M. A. K., & Rezaei, N. (2025) · Springer eBooks · doi:10.1007/978-3-032-00767-4_403
Wang, H., Fu, Y., Lin, G., Zhang, D., Nan, X., Liu, J., Mou, X., Liu, C., Fan, Y., Zheng, T., et al. (2026) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.70159
Struyf, N., Hartmanis, L., Pizarro, L. R., Österroos, A., Bohlin, A., Bengtzén, S., Lehmann, S., Kallioniemi, O., & Erkers, T. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.01.735780
Metadata
- Authors
- Kannan, S., Sutphin, R. M., Hall, M. G., Golfman, L. S., Fang, W., Nolo, R. M., Akers, L. J., Hammitt, R. A., McMurray, J. S., Kornblau, S. M., Melnick, A. M., Figueroa, M. E., & Zweidler-McKay, P. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Department of Pediatric Hematology/Oncology, M.D. Anderson Cancer Center Orlando, Orlando, FL 32806 4
- Cook Children's Medical Center (US)
- Sigma Genosys (United States) (US)
- Weill Cornell Medicine (US)
- Department of Pathology, University of Michigan Health System, Ann Arbor, MI 48109 8
- Division of Pediatrics 1 , 2 , and 3
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2013-01-28
- Volume
- 210
- Issue
- 2
- Pages
- 321-337
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC3570106
- OpenAlex
- W2113096952
- Cited by
- 152
- References
- 59
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 7 · 2023: 8 · 2022: 16 · 2021: 8 · 2020: 8 · 2019: 12 · 2018: 12 · 2017: 8 · 2016: 15 · 2015: 18 · 2014: 20 · 2013: 10
- FWCI
- 15.06
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- cc-by-nc-sa
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (R01CA138816, P30CA016672)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Developmental Biology and Gene Regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Retinoids in leukemia and cellular processes
- Keywords
- Notch signaling, acute myeloid leukemia, Notch1, Notch2, Notch3, Notch4, Hes1, apoptosis, Bcl-2, therapeutic target
- MeSH terms
- Transcription Factor HES-1, Adolescent, Animals, Cell Survival, Child, DNA-Binding Proteins, Humans, Infant, Mutation, RNA, Messenger, RNA, Neoplasm, Transcription Factors, Signal Transduction, Leukemia, Myeloid, Acute, Gene Expression, Tumor Suppressor Protein p53, Mice, SCID, Mice, Inbred NOD, Apoptosis, Mice, Knockout, Homeodomain Proteins, Proto-Oncogene Proteins c-bcl-2, Cell Line, Tumor, Cell Proliferation, Mice, Basic Helix-Loop-Helix Proteins, Receptors, Notch
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.